Research and Markets (http://www.researchandmarkets.com/research/5bf97k/research_report) has announced the addition of the "Concise Analysis of the Chinese Antidiabetic Drug Market" report to their offering.
As China's society is further aging and obesity caused by improved living level and unhealthy lifestyle is increasing, the prevention and cure to diabetes become more difficult. The prevalence rate of diabetes in China increased from less 1% in 1980 to about 5.5% in 2022, 11% in 2013, which become the third chronic disease threatening the health of Chinese people.
The number of diabetes sufferers of China ranks the first in the world. In 2013, the number exceeded 110 million. Meanwhile, there are more than 400 million people in the diabetes prophase so the number will increase high in the next 10 years. The under-control rate of grown-up diabetic sufferers accepting treatment is lower than 40% for lacking medical care.
There are many antidiabetic drug varieties on China market, of which oral hypoglycemic drugs and insulin dominate the market. While new antidiabetic drugs like DPP-4 inhibitor, GLP-1 agonist, SGLT-2 inhibitor, etc. become hotspots in the globe, the classic drugs like Acarbose, Metformin, etc. still occupy most market share in China.
As the prevalence rate is growing and the living level and medical care level are improved, the market size of antidiabetic drugs is enlarged in China. In 2013, the market size exceeded CNY 20 billion. The CAGR in 2009-2013 exceeded 17%. CRI estimates the CAGR of China antidiabetic drug market size will keep 15%.
Key Topics Covered:
1. Overview on Diabetes
2 Therapies on Diabetes and Antidiabetic Drugs, 2009-2013
3 Major Antidiabetic Drugs Applied in Clinic in China, 2009-2013
4 Analysis on China Antidiabetic Drug Market, 2009-2013
5 Major Manufacturing Enterprises (Totals 15-20) in China Antidiabetic Drug Market, 2009-2013
6 Prospect of Global and China Antidiabetic Drug Market, 2014-2018
Eli Lilly and Company
Novo Nordisk (China) Pharmaceutical Co., Ltd.